Opdyta 100 Mg Injection

Description

About Opdyta 100 mg Injection

Opdyta 100 mg Injection contains nivolumab, a monoclonal antibody supplied as a vial for intravenous infusion. It is given by trained healthcare staff, on a schedule set by the treating oncologist.

How it works

Nivolumab is an immune checkpoint inhibitor. T cells carry a receptor called PD-1 that acts as a brake on the immune response; many tumours exploit that brake to avoid being attacked. Nivolumab blocks PD-1, releasing the brake so the body’s own T cells can recognise and attack the cancer. It is an immunotherapy rather than a chemotherapy: it does not kill cancer cells directly.

What it is used for

Nivolumab is used in the treatment of advanced melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial (bladder) cancer, classical Hodgkin lymphoma, and cancers of the head and neck, among other indications. It may be given alone or in combination, depending on the cancer and on previous treatment.

Important safety information

Because nivolumab releases a brake on the immune system, it can cause the immune system to attack healthy tissue. This can affect the bowel, lungs, liver, skin, and hormone glands including the thyroid, pituitary and adrenals, and can occur during treatment or months afterwards. Report any new diarrhoea, breathlessness, cough, rash, severe tiredness, unusual thirst or headache promptly, however mild it seems: these reactions are treatable but need to be recognised early. Blood tests including thyroid and liver function are monitored. Tell your doctor if you have an autoimmune condition, have had an organ transplant, or take medicines that suppress the immune system.

This is a prescription-only medicine. It should be used only under the supervision of a qualified healthcare professional, who will decide whether it is suitable for you and at what dose.